Molecular immune pathogenesis and diagnosis of COVID-19

Xiaowei Li, Manman Geng, Yizhao Peng, Liesu Meng, Shemin Lu, Xiaowei Li, Manman Geng, Yizhao Peng, Liesu Meng, Shemin Lu

Abstract

Coronavirus disease 2019 (COVID-19) is a kind of viral pneumonia which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The emergence of SARS-CoV-2 has been marked as the third introduction of a highly pathogenic coronavirus into the human population after the severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV) in the twenty-first century. In this minireview, we provide a brief introduction of the general features of SARS-CoV-2 and discuss current knowledge of molecular immune pathogenesis, diagnosis and treatment of COVID-19 on the base of the present understanding of SARS-CoV and MERS-CoV infections, which may be helpful in offering novel insights and potential therapeutic targets for combating the SARS-CoV-2 infection.

Keywords: Coronavirus; MERS-CoV; Pathogenesis; SARS-CoV; SARS-CoV-2.

Conflict of interest statement

The authors declare that there are no conflicts of interest.

© 2020 Xi'an Jiaotong University. Production and hosting by Elsevier B.V.

Figures

Graphical abstract
Graphical abstract
Fig. 1
Fig. 1
The phylogenetic tree of SARS-like coronaviruses complete genome sequences and genome of SARS-CoV, MERS-CoV and SARSCoV- 2. (A) This phylogeny shows evolution of SARS-like β-coronaviruses including samples from human (n = 20), bat (n = 22), civet (n = 3) and pangolin (n = 6). The phylogenetic tree of complete genome sequences of coronaviruses was obtained and analyzed with Nextstrain (https://github.com/blab/sars-like-cov). (B) Coronaviruses form enveloped and spherical particles of 100–160 nm in diameter. They contain a positivesense single stranded RNA (ssRNA) genome of 26–32 kb in size. In SARS-CoV, MERS-CoV and SARS-CoV-2, the 5′-terminal two-thirds of the genome ORF1a/b encodes polyproteins, which form the viral replicase transcriptase complex. The other ORFs on the one-third of the genome encode four main structural proteins: spike (S), envelope (E), nucleocapsid (N) and membrane (M) proteins, as well as several accessory proteins.

References

    1. Zhou P., Yang X.L., Wang X.G. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020 doi: 10.1038/s41586-020-2012-7.
    1. de Wit E., van Doremalen N., Falzarano D. SARS and MERS: recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 2016;14:523–534. doi: 10.1038/nrmicro.2016.81.
    1. Wu J.T., Leung K., Leung G.M. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet. 2020 doi: 10.1016/S0140-6736(20)30260-9.
    1. Su S., Wong G., Shi W. Epidemiology, Genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016;24:490–502. doi: 10.1016/j.tim.2016.03.003.
    1. Perlman S. J. Netland Coronaviruses post-SARS: update on replication and pathogenesis. Nat. Rev. Microbiol. 2009;7:439–450. doi: 10.1038/nrmicro2147.
    1. Lu R., Zhao X., Li J. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020 doi: 10.1016/S0140-6736(20)30251-8.
    1. Fehr A.R., Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol. Biol. 2015;1282:1–23. doi: 10.1007/978-1-4939-2438-7_1.
    1. Masters P.S. The molecular biology of coronaviruses. Adv. Virus Res. 2006;66:193–292. doi: 10.1016/S0065-3527(06)66005-3.
    1. Knoops K., Kikkert M., Worm S.H. SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum. PLoS Biol. 2008;6 doi: 10.1371/journal.pbio.0060226. e226.
    1. Li W., Moore M.J., Vasilieva N. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450–454. doi: 10.1038/nature02145.
    1. Ge X.Y., Li J.L., Yang X.L. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature. 2013;503:535–538. doi: 10.1038/nature12711.
    1. Chinese SARS Molecular Epidemiology Consortium Chinese Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China. Science. 2004;303:1666–1669. doi: 10.1126/science.1092002.
    1. Raj V.S., Mou H., Smits S.L. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013;495:251–254. doi: 10.1038/nature12005.
    1. Barlan A., Zhao J., Sarkar M.K. Receptor variation and susceptibility to Middle East respiratory syndrome coronavirus infection. J. Virol. 2014;88:4953–4961. doi: 10.1128/JVI.00161-14.
    1. Huang C., Wang Y., Li X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 doi: 10.1016/S0140-6736(20)30183-5.
    1. Peiris J.S., Guan Y., Yuen K.Y. Severe acute respiratory syndrome. Nat. Med. 2004;10:S88–S97. doi: 10.1038/nm1143.
    1. Wu F., Zhao S., Yu B. A new coronavirus associated with human respiratory disease in China. Nature. 2020 doi: 10.1038/s41586-020-2008-3.
    1. Jeffers S.A., Tusell S.M., Gillim-Ross L. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proc. Natl. Acad. Sci. U.S.A. 2004;101:15748–15753. doi: 10.1073/pnas.0403812101.
    1. Simmons G., Reeves J.D., Rennekamp A.J. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc. Natl. Acad. Sci. U.S.A. 2004;101:4240–4245. doi: 10.1073/pnas.0306446101.
    1. Belouzard S., Chu V.C., Whittaker G.R. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proc. Natl. Acad. Sci. U.S.A. 2009;106:5871–5876. doi: 10.1073/pnas.0809524106.
    1. Millet J.K., Whittaker G.R. Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein. Proc. Natl. Acad. Sci. U.S.A. 2014;111:15214–15219. doi: 10.1073/pnas.1407087111.
    1. Wang H., Yang P., Liu K. SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway. Cell Res. 2008;18:290–301. doi: 10.1038/cr.2008.15.
    1. Kuba K., Imai Y., Ohto-Nakanishi T. Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters. Pharmacol. Ther. 2010;128:119–128. doi: 10.1016/j.pharmthera.2010.06.003.
    1. Liu J., Wu P., Gao F. Novel immunodominant peptide presentation strategy: a featured HLA-A∗2402-restricted cytotoxic T-lymphocyte epitope stabilized by intrachain hydrogen bonds from severe acute respiratory syndrome coronavirus nucleocapsid protein. J. Virol. 2010;84:11849–11857. doi: 10.1128/JVI.01464-10.
    1. Keicho N., Itoyama S., Kashiwase K. Association of human leukocyte antigen class II alleles with severe acute respiratory syndrome in the Vietnamese population. Hum. Immunol. 2009;70:527–531. doi: 10.1016/j.humimm.2009.05.006.
    1. Chen Y.M., Liang S.Y., Shih Y.P. Epidemiological and genetic correlates of severe acute respiratory syndrome coronavirus infection in the hospital with the highest nosocomial infection rate in Taiwan in 2003. J. Clin. Microbiol. 2006;44:359–365. doi: 10.1128/JCM.44.2.359-365.2006.
    1. Wang S.F., Chen K.H., Chen M. Human-leukocyte antigen class I Cw 1502 and class II DR 0301 genotypes are associated with resistance to severe acute respiratory syndrome (SARS) infection. Viral Immunol. 2011;24:421–426. doi: 10.1089/vim.2011.0024.
    1. Hajeer A.H., Balkhy H., Johani S. Association of human leukocyte antigen class II alleles with severe Middle East respiratory syndrome-coronavirus infection. Ann. Thorac. Med. 2016;11:211–213. doi: 10.4103/1817-1737.185756.
    1. Tu X., Chong W.P., Zhai Y. Functional polymorphisms of the CCL2 and MBL genes cumulatively increase susceptibility to severe acute respiratory syndrome coronavirus infection. J. Infect. 2015;71:101–109. doi: 10.1016/j.jinf.2015.03.006.
    1. Li G., Chen X., Xu A. Profile of specific antibodies to the SARS-associated coronavirus. N. Engl. J. Med. 2003;349:508–509. doi: 10.1056/NEJM200307313490520.
    1. Xu Z., Shi L., Wang Y. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Resp. Med. 2020 doi: 10.1016/S2213-2600(20)30076-X.
    1. Fan Y.Y., Huang Z.T., Li L. Characterization of SARS-CoV-specific memory T cells from recovered individuals 4 years after infection. Arch. Virol. 2009;154:1093–1099. doi: 10.1007/s00705-009-0409-6.
    1. Tang F., Quan Y., Xin Z.T. Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study. J. Immunol. 2011;186:7264–7268. doi: 10.4049/jimmunol.0903490.
    1. Zhao J., Li K., Wohlford-Lenane C. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc. Natl. Acad. Sci. U.S.A. 2014;111:4970–4975. doi: 10.1073/pnas.1323279111.
    1. Williams A.E., Chambers R.C. The mercurial nature of neutrophils: still an enigma in ARDS? Am. J. Physiol. Lung Cell Mol. Physiol. 2014;306:L217–L230. doi: 10.1152/ajplung.00311.2013.
    1. Channappanavar R., Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin. Immunopathol. 2017;39:529–539. doi: 10.1007/s00281-017-0629-x.
    1. Cameron M.J., Bermejo-Martin J.F., Danesh A. Human immunopathogenesis of severe acute respiratory syndrome (SARS) Virus Res. 2008;133:13–19. doi: 10.1016/j.virusres.2007.02.014.
    1. Min C.K., Cheon S., Ha N.Y. Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity. Sci. Rep. 2016;6:25359. doi: 10.1038/srep25359.
    1. Snijder E.J., van der Meer Y., Zevenhoven-Dobbe J. Ultrastructure and origin of membrane vesicles associated with the severe acute respiratory syndrome coronavirus replication complex. J. Virol. 2006;80:5927–5940. doi: 10.1128/JVI.02501-05.
    1. Channappanavar R., Fehr A.R., Vijay R. Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe. 2016;19:181–193. doi: 10.1016/j.chom.2016.01.007.
    1. Channappanavar R., Fehr A.R., Zheng J. IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. J. Clin. Invest. 2019;130:3625–3639. doi: 10.1172/JCI126363.
    1. Niemeyer D., Zillinger T., Muth D. Middle East respiratory syndrome coronavirus accessory protein 4a is a type I interferon antagonist. J. Virol. 2013;87:12489–12495. doi: 10.1128/JVI.01845-13.
    1. Yang Y., Zhang L., Geng H. The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists. Protein Cell. 2013;4:951–961. doi: 10.1007/s13238-013-3096-8.
    1. Menachery V.D., Schafer A., Burnum-Johnson K.E. MERS-CoV and H5N1 influenza virus antagonize antigen presentation by altering the epigenetic landscape. Proc. Natl. Acad. Sci. U.S.A. 2018;115:E1012–E1021. doi: 10.1073/pnas.1706928115.
    1. Corman V.M., Landt O., Kaiser M. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25 doi: 10.2807/1560-7917.ES.2020.25.3.2000045.
    1. Chu D.K.W., Pan Y., Cheng S.M.S. Molecular diagnosis of a novel coronavirus (2019-nCoV) causing an outbreak of pneumonia. Clin. Chem. 2020 doi: 10.1093/clinchem/hvaa029.
    1. To K.K., Tsang O.T., Chik-Yan Yip C. Consistent detection of 2019 novel coronavirus in saliva. Clin. Infect. Dis. 2020 doi: 10.1093/cid/ciaa149.
    1. Woo P.C., Lau S.K., Wong B.H. Differential sensitivities of severe acute respiratory syndrome (SARS) coronavirus spike polypeptide enzyme-linked immunosorbent assay (ELISA) and SARS coronavirus nucleocapsid protein ELISA for serodiagnosis of SARS coronavirus pneumonia. J. Clin. Microbiol. 2005;43:3054–3058. doi: 10.1128/JCM.43.7.3054-3058.2005.
    1. Xie X., Zhong Z., Zhao W. Chest CT for typical 2019-nCoV pneumonia: relationship to negative RT-PCR testing. Radiology. 2020 doi: 10.1148/radiol.2020200343.
    1. Yam W.C., Chan K.H., Poon L.L. Evaluation of reverse transcription-PCR assays for rapid diagnosis of severe acute respiratory syndrome associated with a novel coronavirus. J. Clin. Microbiol. 2003;41:4521–4524. doi: 10.1128/jcm.41.10.4521-4524.2003.
    1. Pan Y., Guan H., Zhou S. Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan, China. Eur. Radiol. 2020 doi: 10.1007/s00330-020-06731-x.
    1. Shi H., Han X., Zheng C. Evolution of CT manifestations in a patient recovered from 2019 novel coronavirus (2019-nCoV) pneumonia in Wuhan, China. Radiology. 2020 doi: 10.1148/radiol.2020200269.
    1. Chung M., Bernheim A., Mei X. CT imaging features of 2019 novel coronavirus (2019-nCoV) Radiology. 2020 doi: 10.1148/radiol.2020200230.
    1. Ooi G.C., Khong P.L., Muller N.L. Severe acute respiratory syndrome: temporal lung changes at thin-section CT in 30 patients. Radiology. 2004;230:836–844. doi: 10.1148/radiol.2303030853.
    1. Ajlan A.M., Ahyad R.A., Jamjoom L.G. Middle East respiratory syndrome coronavirus (MERS-CoV) infection: chest CT findings. AJR Am. J. Roentgenol. 2014;203:782–787. doi: 10.2214/AJR.14.13021.
    1. Zumla A., Chan J.F., Azhar E.I. Coronaviruses - drug discovery and therapeutic options. Nat. Rev. Drug Discov. 2016;15:327–347. doi: 10.1038/nrd.2015.37.
    1. Groneberg D.A., Hilgenfeld R., Zabel P. Molecular mechanisms of severe acute respiratory syndrome (SARS) Respir. Res. 2005;6:8. doi: 10.1186/1465-9921-6-8.
    1. Lo M.K., Jordan R., Arvey A. GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. Sci. Rep. 2017;7:43395. doi: 10.1038/srep43395.
    1. Sheahan T.P., Sims A.C., Leist S.R. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat. Commun. 2020;11:222. doi: 10.1038/s41467-019-13940-6.
    1. de Wit E., Feldmann F., Cronin J. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc. Natl. Acad. Sci. U.S.A. 2020 doi: 10.1073/pnas.1922083117.
    1. Lo M.K., Feldmann F., Gary J.M. Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge. Sci. Transl. Med. 2019;11 doi: 10.1126/scitranslmed.aau9242.
    1. Holshue M.L., DeBolt C., Lindquist S. First case of 2019 novel coronavirus in the United States. N. Engl. J. Med. 2020 doi: 10.1056/NEJMoa2001191.
    1. Wang M., Cao R., Zhang L. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 doi: 10.1038/s41422-020-0282-0.
    1. De Clercq E. New nucleoside analogues for the treatment of hemorrhagic fever virus infections. Chem. Asian J. 2019;14:3962–3968. doi: 10.1002/asia.201900841.
    1. Chen Y., Liu Q., Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J. Med. Virol. 2020;92:418–423. doi: 10.1002/jmv.25681.
    1. Chen L., Gui C., Luo X. Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro. J. Virol. 2005;79:7095–7103. doi: 10.1128/JVI.79.11.7095-7103.2005.
    1. Jo S., Kim S., Shin D.H. Inhibition of SARS-CoV 3CL protease by flavonoids. J. Enzym. Inhib. Med. Chem. 2020;35:145–151. doi: 10.1080/14756366.2019.1690480.
    1. Park J.Y., Jeong H.J., Kim J.H. Diarylheptanoids from Alnus japonica inhibit papain-like protease of severe acute respiratory syndrome coronavirus. Biol. Pharm. Bull. 2012;35:2036–2042. doi: 10.1248/bpb.b12-00623.
    1. Mair-Jenkins J., Saavedra-Campos M., Baillie J.K. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J. Infect. Dis. 2015;211:80–90. doi: 10.1093/infdis/jiu396.
    1. Koenig K.L. Identify-Isolate-Inform: a modified tool for initial detection and management of Middle East Respiratory Syndrome patients in the emergency department. West. J. Emerg. Med. 2015;16:619–624. doi: 10.5811/westjem.2015.7.27915.
    1. Tian X., Li C., Huang A. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg. Microb. Infect. 2020;9:382–385. doi: 10.1080/22221751.2020.1729069.
    1. Zhang L., Liu Y. Potential interventions for novel coronavirus in China: a systematic review. J. Med. Virol. 2020 doi: 10.1002/jmv.25707.
    1. Graham R.L., Donaldson E.F., Baric R.S. A decade after SARS: strategies for controlling emerging coronaviruses. Nat. Rev. Microbiol. 2013;11:836–848. doi: 10.1038/nrmicro3143.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe